Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib Combined With Cobimetinib in Advanced ALK+ NSCLC
NCT03202940Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2017
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cobimetinib in non-small cell lung cancer (NSCLC), sponsored by Massachusetts General Hospital. Started Sep 2017; status: active, not recruiting.
02
Drugs
cobimetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03202940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03202940.